Aspire BioPharma, Inc. (NASDAQ:ASBP) — Market Cap & Net Worth
Market Cap & Net Worth: Aspire BioPharma, Inc. (ASBP)
Aspire BioPharma, Inc. (NASDAQ:ASBP) has a market capitalization of $10.09 Million ($10.09 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27134 globally and #5620 in its home market, demonstrating a 5.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aspire BioPharma, Inc.'s stock price $9.12 by its total outstanding shares 1295234 (1.30 Million). Also see ASBP current and non-current assets for a full breakdown of the balance sheet.
Aspire BioPharma, Inc. Market Cap History: 2025 to 2026
Aspire BioPharma, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $170.84K to $11.81 Million (124.63% CAGR). Also see cash flow conversion of Aspire BioPharma, Inc. for how efficiently the company converts equity into cash flow.
Aspire BioPharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aspire BioPharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Aspire BioPharma, Inc. stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
27.55x
Aspire BioPharma, Inc.'s market cap is 27.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $170.84K | $6.20K | -$24.48 Million | 27.55x | N/A |
Competitor Companies of ASBP by Market Capitalization
Companies near Aspire BioPharma, Inc. in the global market cap rankings as of September 18, 2026. Review ASBP intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Aspire BioPharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Aspire BioPharma, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Aspire BioPharma, Inc.'s market cap moved from $170.84K to $ 11.81 Million, with a yearly change of 124.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.81 Million | +6814.33% |
| 2025 | $170.84K | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Aspire BioPharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.09 Million USD |
| MoneyControl | $10.09 Million USD |
| MarketWatch | $10.09 Million USD |
| marketcap.company | $10.09 Million USD |
| Reuters | $10.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more